retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Retatrutide: How the Compares to Tirzepatide GLP-3 Dosing Protocol UAE: How
Description
Food and Drug Administration (FDA) has approved semaglutide (marketed as Wegovy) and Tirzepatide (marketed as Zepbound) specifically for chronic weight management in adults with obesity or overweight individuals with at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, or high cholesterol
Accordingly, dulaglutide, liraglutide and semaglutide are indicated to reduce cardiovascular risk in people with type 2 diabetes
[DOI] [PMC free article] [PubMed] [Google Scholar] 80
Kario K, Wang JG, Chia YC, Wang TD, Li Y, Siddique S, et al
However, while GLP-1 RAs did not exhibit an increased risk of acute pancreatitis, DPP-4 inhibitors demonstrated a notable risk elevation (rate ratio, 1.75) [53]
